The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and ...

The US Food and Drug Administration (FDA) has approved two of Merck & Co’s (MSD) Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each combined with Padcev ...

Alteogen announced on September 18 that MSD's Keytruda SC (marketed as Keyject in Japan), a subcutaneous injection (SC) ...

In September 2025, the FDA approved KEYTRUDA QLEX and it is now approved for adults in all the same solid tumor indications as KEYTRUDA. In pre-market trading on NYSE, Merck shares are up 0.06 percent ...

Merck Receives Approval in Japan for Keytruda Qlex MT Sep. 18 Merck Receives Positive Eu CHMP Opinion for Keytruda Plus Padcev as Perioperative Treatment for Resectable Muscle-Invasive Bladder Cancer ...

Drug major Merck & Co., Inc. ( MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending approval of ...

Merck & Co. stock benefits from the September 21, 2026 approval of Keytruda QLEX in Japan, adding a new subcutaneous option ...

A breakthrough melanoma vaccine is generating excitement among doctors and patients alike. But one of the biggest questions people are asking after the latest news is whether Moderna's cancer vaccine ...